V
VIRIOS THERAPEUTICS LLC
NASDAQ: VIRI (Virios Therapeutics, Inc.)
Last update: 12 hours ago0.178
-0.01 (-3.58%)
| Previous Close | 0.185 |
| Open | 0.185 |
| Volume | 417,718 |
| Avg. Volume (3M) | 1,127,908 |
| Market Cap | 4,940,906 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2024 - 15 Nov 2024 |
| Diluted EPS (TTM) | -0.230 |
| Current Ratio (MRQ) | 7.27 |
| Operating Cash Flow (TTM) | -4.18 M |
| Levered Free Cash Flow (TTM) | -2.43 M |
| Return on Assets (TTM) | -67.76% |
| Return on Equity (TTM) | -119.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Virios Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.6 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | -1.7 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.65 |
Select this tab to load the latest available analysis.
|
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”) and Long-COVID (“LC”). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.74% |
| % Held by Institutions | 3.60% |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |